Matt Gaetz has a new gig lined up as an anchor on conservative news network OANMSI Unveils New Gaming Monitor With 80Gbps DisplayPort 2.1 - ChannelNewsNEW YORK (AP) — Stocks fell in morning trading Friday as Wall Street closes out a holiday-shortened week. The S&P 500 fell 1.4%, with more than 80% of stocks in the benchmark index losing ground. Still, the index is managing to hold onto a modest gain for the week. The Dow Jones Industrial Average fell 402 points, or 0.9%, to 42,945 as of 10:41 a.m. Eastern time. The Nasdaq composite fell 2%. Both the Dow and the Nasdaq are also holding on to weekly gains. Technology stocks were the biggest drag on the market Friday. Semiconductor giant Nvidia slumped 3.2%. Its enormous valuation gives it an outsize influence on indexes. Other Big Tech stocks losing ground included Microsoft, with a 2.2% decline. A wide range of retailers also fell. Amazon fell 2.2% and Best Buy slipped 1.9%. The sector is being closely watched for clues on how it performed during the holiday shopping season. Energy was the only sector within the S&P 500 rising. It gained 0.5% as crude oil prices rose 0.8%. Investors don't have much in the way of corporate or economic updates to review as the market moves closer to another standout annual finish. The S&P 500 is on track for a gain of around 25% in 2024. That would mark a second consecutive yearly gain of more than 20%, the first time that has happened since 1997-1998. The gains have been driven partly by upbeat economic data showing that consumers continued spending and the labor market remained strong. Inflation, while still high, has also been steadily easing. A report on Friday showed that sales and inventory estimates for the wholesales trade industry fell 0.2% in November, following a slight gain in October. That weaker-than-expected report follows an update on the labor market Thursday that showed unemployment benefits held steady last week. In Asia, Japan’s benchmark index surged as the yen remained weak against the dollar. Stocks in South Korea fell after the main opposition party voted to impeach the country’s acting leader. Markets in Europe gained ground. Bond yields held relatively steady. The yield on the 10-year Treasury remained at 4.59% from late Thursday. The yield on the two-year Treasury slipped to 4.32% from 4.33% late Thursday. Wall Street will have more economic updates to look forward to next week, including reports on pending home sales and home prices. There will also be reports on U.S. construction spending and snapshots of manufacturing activity.
BIAO Partners with Wintermute: $BIAO - The Biggest Meme in the East Goes Global!CreateAI Announces Results of 2024 Annual Meeting of Stockholders
Utah DWR stocks 12.8M fish in 2024, the most in last 5 yearsS&P/TSX composite closes up nearly 150 points on Monday, U.S. stock markets up
If you’re ready to have more fun, connect with friends and break out of your comfort zone in 2025, immersive experiences are the way to go. These creative activities blend entertainment, art and technology into unforgettable nights out. Immersive nightlife goes beyond the conventional dance floor or cocktail bar, integrating interactive storytelling, cutting-edge technology, and multisensory elements to create environments where guests become part of the experience. Think of it as stepping into a live-action movie, an art installation, or a futuristic game. From AI-enhanced light shows to rooms where walls respond to your movements, the goal is to engage every sense and leave patrons awestruck. These experiences often incorporate elements of escapism, transporting attendees to entirely new worlds. Whether it’s a speakeasy hidden inside a labyrinthine puzzle or a nightclub designed as a space station, immersive nightlife challenges the imagination while delivering high-energy fun. One of the most popular types of immersive nightlife experiences is escape rooms, which have been growing in popularity in the U.S. over the past 10 years. These interactive adventures challenge groups to solve puzzles, uncover clues, and work together to “escape” within a set time limit. Modern escape rooms often incorporate high-tech elements like projection mapping, augmented reality, and even live actors to elevate the experience. Themes range from solving a heist to surviving a zombie apocalypse, making every visit unique. Escape rooms have become their own industry, with chains like Escapology – whose locations include Los Angeles, San Diego and Riverside counties – as well as highly creative smaller operations like Wizards & Wires Escape Games in Riverside, Unlocked in Costa Mesa and Lara’s Labyrinth in San Diego For nightlife enthusiasts, late-night escape room events with added theatrical elements or themed cocktails are a fresh twist on traditional social outings. Virtual reality (VR) lounges are another thrilling addition to the immersive nightlife scene. These venues offer cutting-edge VR experiences where guests can dive into fantastical worlds, compete in multiplayer games, or even participate in interactive storytelling. With high-resolution headsets and motion-tracking technology, these lounges allow patrons to fully immerse themselves in otherworldly adventures.Many VR lounges pair these experiences with trendy bar menus, creating a social hub where guests can relax, compare scores, and extend the fun after their virtual escapades. Popular SoCal VR hotspots include Los Virtuality in Los Angeles, Sandbox VR in Woodland Hills and The GRID in Oceanside. Interactive art museums and installations bring a creative flair to immersive nightlife. These spaces invite visitors to become part of the artwork itself, using touch, sound, and motion to activate exhibits. Picture walking through rooms that react to your presence with cascading lights, evolving soundscapes, or transformative projections. Some venues even host nighttime events with live music, themed cocktails, and exclusive access to exhibits, creating a blend of culture and entertainment that’s perfect for a night out. These art-driven experiences are not only visually stunning but also provide a unique way to explore creativity while socializing. A great example is WNDR Museum in San Diego’s Gaslamp Quarter where you can take in over 15 installations of awe-inspiring immersive art. The news and editorial staffs of Southern California News Group and The San Diego Union-Tribune had no role in this post’s preparation.Arbor Battery Innovations to Present Revolutionary Lithium-Ion Advancements at AABC 2024
America's technology blind spotJarvis Moss, Jonas Sirtautas lead Radford past Bucknell 74-70 in OT
Evaluating strategic options for iopofosine I 131 a late-stage clinical program with compelling Phase 2 data and a substantial market opportunity Focusing on advancing radiotherapeutic assets including alpha- and Auger-emitting radioconjugates into Phase 1 solid tumor studies FLORHAM PARK, N.J., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announces a strategic update on its clinical development programs for its proprietary phospholipid ether drug conjugate platform that delivers a broad array of therapeutic modalities to target cancers. Due to recent communications with the U.S. Food and Drug Administration (FDA, or the Agency) regarding a confirmatory study to support accelerated approval and the regulatory submission for iopofosine I 131, the Company has decided to pursue strategic options for the further development and commercialization of this product candidate. The CLOVER-WaM study was conducted in accordance with earlier FDA communications from an end of Phase 2 meeting and from a meeting in early 2024, during which the Company was informed that positive results for major response rate (MRR) as the primary endpoint could be acceptable to support accelerated approval of iopofosine I 131 as a treatment for Waldenstrom's macroglobulinemia (WM). Based upon a recent Type-C meeting with the FDA, the Company now believes that a submission seeking accelerated approval would need to be based on the MRR data from CLOVER-WaM and enrollment in a randomized, controlled confirmatory study that is designed to generate data on progression-free survival (PFS). "While iopofosine I 131's positive WM data along with the high unmet medical need for these patients support further investment, we have determined that such a program may best be brought to market by a larger organization with greater resources. Importantly, partnering or divesting this program supports our commitment to providing this potentially life-saving drug to the patients who need it as quickly as possible,” stated James Caruso, president and CEO of Cellectar. "We believe iopofosine I 131 represents a compelling opportunity as it has shown strong efficacy and good tolerability based on our clinical studies. Moreover, the commercial work we conducted demonstrates iopofosine I 131's substantial market opportunity based upon the product profile, which includes off-the-shelf global distribution, orphan pricing and existing unmet medical need.” Cellectar remains confident in the potential of its phospholipid ether drug conjugate platform and the targeted radiotherapies in its development pipeline. Iopofosine I 131's clinical success validates the platform's ability to target cancers and Cellectar will leverage its experience to focus on the development of its earlier clinical programs. Specifically, Cellectar will focus on those assets it believes have the highest therapeutic potential and opportunity for value creation. As highlighted by recent acquisitions and collaborations within the radiopharmaceutical sector, precision isotopes like alpha- and Auger-emitters have emerged as the leading therapeutics of interest. Consequently, the Company will now focus its resources on targeting solid tumors by advancing CLR 121225, its actinium-225 based program, and CLR 121125, its iodine-125 Auger-emitting program into the clinic. Cellectar expects to file Investigational New Drug applications in the first half of 2025 for both CLR-121225 and CLR-121125, which will allow the initiation of Phase 1 clinical studies in solid tumor cancers. Both programs have demonstrated robust in vivo activity, tolerability, excellent targeting and uptake in preclinical solid tumor models. The Company believes this approach will provide an expedited timeframe to achieve safety and proof-of-concept data in patients. The Company's strategic reprioritization will impact all departments and result in an immediate reduction in headcount of approximately 60%, which should be complete by the end of the fourth quarter 2024. The Company anticipates that the implementation of the restructuring will extend its cash runway into the third quarter of 2025. "We are being methodical in our efforts to reorganize the company with the goal of conserving cash while maintaining the flexibility to execute immediate priorities and build for long-term growth and value creation. This reorganization is difficult but necessary for the future growth potential of Cellectar,” said Mr. Caruso. "I want to extend my deepest gratitude to our departing employees for their significant contributions to our work and their dedication to making a difference in the lives of patients.” About Cellectar Biosciences, Inc. Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and through research and development collaborations. The company's core objective is to leverage its proprietary Phospholipid Drug Conjugate TM (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments, delivering improved efficacy and better safety as a result of fewer off-target effects. The company's product pipeline includes lead asset, iopofosine I 131, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), CLR 121225, an actinium-225 based program being targeted to several solid tumors with significant unmet need, such as pancreatic cancer, CLR 121125, an iodine-125 Auger-emitting program targeted in other solid tumors, such as triple negative breast, lung and colorectal, proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. In addition, iopofosine I 131 is under evaluation in Phase 2b studies for relapsed or refractory multiple myeloma (MM) and central nervous system (CNS) lymphoma, alongside the CLOVER-2 Phase 1b study, targeting pediatric patients with high-grade gliomas, for which Cellectar is eligible to receive a Pediatric Review Voucher from the FDA upon approval. The FDA has also granted iopofosine I 131 Orphan Drug and Fast Track Designations for various cancer indications. New data from the CLOVER-WaM Phase 2 clinical trial were recently presented in an oral presentation at the 66th American Society of Hematology Annual Meeting and Exposition (ASH 2024). For more information, please visit www.cellectar.com or join the conversation by liking and following us on the company's social media channels: Twitter, LinkedIn, and Facebook. Forward-Looking Statement Disclaimer This news release contains forward-looking statements. You can identify these statements by our use of words such as "may," "expect," "believe," "anticipate," "intend," "could," "estimate," "continue," "plans," or their negatives or cognates. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to raise additional capital, uncertainties related to the disruptions at our sole source supplier of iopofosine, the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, patient enrollment and the completion of clinical studies, the FDA review process and other government regulation, our ability to obtain regulatory exclusivities, the availability of priority review vouchers, our ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement. A complete description of risks and uncertainties related to our business is contained in our periodic reports filed with the Securities and Exchange Commission including our Form 10-K/A for the year ended December 31, 2023, and our Form 10-Q for the quarter ended September 30, 2024. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements. Contacts MEDIA: Christy Maginn Bliss Bio Health 703-297-7194 [email protected] INVESTORS: Anne Marie Fields Precision AQ 212-362-1200 [email protected]
The $11.50 cleaning product that cleared my stinky drainsDrama for DOGE bros: Ramaswamy caught on tape trashing Musk
None
Kurtis Rourke has made the Jon Cornish Trophy a family affair. The Indiana quarterback received the award Monday, which is presented annually to the top Canadian playing football in the NCAA. Rourke’s older brother, Nathan, currently with the CFL’s B.C. Lions, won the award twice in 2017 and 2018 at Ohio. “It’s awesome,” Rourke said. “Kind of getting introduced to the Jon Cornish Trophy back when Nathan won it a couple of times, I wanted to be able to have a shot and it was one of my goals to be in the conversation, be in the running. “It just means a ton to be recognized just because Canadian athletes don’t get recognized too often. I’m just so glad we’re able to get that recognition and continue to do it for our country.” Rourke finished first in voting ahead of Montreal’s Dariel Djabome, a junior linebacker at Rutgers. Stanford receiver Elic Ayomanor, last year’s winner, was third, followed by Vancouver’s Ty Benefield (sophomore safety, Boise State) and Jett Elad of Mississauga, Ont., a senior safety at UNLV. Cornish, of New Westminster, B.C., was a standout running back at Kansas who went on to have a decorated CFL career with the Calgary Stampeders (2007-15) before being inducted into the Canadian Football Hall of Fame in 2019. Rourke transferred to Indiana last December to boost his NFL draft stock after five years at Ohio, where he began as a backup to his older brother. The junior Rourke then captured the ‘22 MAC offensive player of the year award despite suffering a season-ending knee injury before heading to Indiana after the 2023 season. Rourke was instrumental in Indiana — traditionally known as a basketball school — emerging as a Big Ten contender in head coach Curt Cignetti’s first season. After winning 11 of their first 12 games, the Hoosiers’ stellar campaign ended with a 27-17 loss to Notre Dame in the opening game of the expanded U.S. college football playoff bracket. Rourke finished 20-of-33 passing for 215 yards with two touchdowns and an interception in that contest. Overall, Rourke completed 222 of 320 passes (69.4 per cent) for 3,042 yards with 29 TDs and five interceptions. “What a privilege, opportunity to come join a program that had so much to prove,” Rourke said. “It kind of aligned with what I was wanting to do, which was prove I could play at a higher level.” The six-foot-five, 223-pound Rourke was named a finalist for the Manning Award, presented annually to the NCAA’s top quarterback. He was also ninth in voting for the Heisman Trophy as U.S. college football’s outstanding player. “College football has been everything to me,” Rourke said. “Starting off my freshman year to be able to watch Nathan grow and play in his senior year and just learn from him in both how to live a college life but also be a college quarterback as well. “I won’t forget my time at Ohio at all, it really created me and moulded me into the person, player I am. I’m extremely grateful for the entire college football experience.” The former Holy Trinity star becomes just the second Canadian high school graduate to claim the Jon Cornish Trophy. Chuba Hubbard, of Sherwood Park, Alta., and currently with the NFL’s Carolina Panthers, did so in 2019 while at Oklahoma State. The six-foot-two, 240-pound Djabome recorded 102 tackles (48 solo), three sacks and two forced fumbles this season. Rutgers faces Kansas State in the Rate Bowl on Boxing Day. The six-foot-two, 210-pound Ayomanor, a redshirt junior, was one of the few bright spots this season for Stanford (3-9). He registered 63 catches for 831 yards and six TDs after recording 62 receptions for 1,013 yards and six touchdowns in 2023. Last week, Ayomanor declared for the ‘25 NFL draft. The six-foot-two, 204-pound Benefield led Boise State in tackles (73), solo tackles (53) and interceptions (two) while also registering five tackles for a loss, a forced fumble and two recoveries. The Broncos are the third seed in U.S. college football’s expanded playoffs and face Penn State in the Fiesta Bowl on Dec. 31. Elad registered 55 tackles, an interception and six pass knockdowns during the regular season. He added 12 tackles (nine solo) and a sack in the Runnin’ Rebels’ 24-13 win over Cal in the Art of Sport LA Bowl to finish with an 11-3 overall record.